You are here

AstraZeneca expects vaccine data this year, sales beat estimates

af_astrazeneca_051120.jpg
AstraZeneca, the British drugmaker working on one of the world's leading Covid-19 vaccine candidates, on Thursday beat third-quarter sales estimates as demand for its diverse portfolio of drugs remained strong during Covid-19 pandemic lockdowns, and it maintained its 2020 forecasts.

[FRANKFURT] AstraZeneca, the British drugmaker working on one of the world's leading Covid-19 vaccine candidates, on Thursday beat third-quarter sales estimates as demand for its diverse portfolio of drugs remained strong during Covid-19 pandemic lockdowns, and it maintained its 2020 forecasts.

The company reiterated it expected results from the late-stage trials on its experimental Covid-19 vaccine later this year, depending on the rate of infection among trial participants.

Product sales, which exclude payments from collaborations, rose 7 per cent to US$6.52 billion for the three months ended Sept 30 on a constant-currency basis, ahead of a company-compiled consensus of US$6.50 billion.

However, the company reported core earnings of 94 US cents per share, lower than analysts' expectations of 98 cents.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes